Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + dacarbazine
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral (lenvatinib), Intravenous (dacarbazine)
01
Overview
**lenvatinib + dacarbazine** is a combination of two pharmaceutical agents used as a first-line therapy in patients with advanced-stage melanoma. **Lenvatinib** is a multi-targeted tyrosine kinase inhibitor that blocks the activity of multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), fibroblast growth factor receptors (FGFR-1), platelet-derived growth factor receptor beta (PDGFR-β), and KIT. **Dacarbazine** is a cytotoxic alkylating agent that disrupts DNA synthesis. This combination is explored to leverage lenvatinib's antiangiogenic and antiproliferative effects with dacarbazine's cytotoxicity to improve outcomes in metastatic melanoma and potentially other solid tumors[2][3].
- Other names
- lenvatinib + dacarbazine
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + dacarbazine.